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In the last decade, peripheral blood was the main source of hematopoietic stem cells (HSC) for autologous and
allogeneic transplantation. The exact mechanisms of HSC mobilization are still not clear and the efﬁcacy of
the procedure is hardly predictable. Ligand-receptor interactions of adhesion molecules, such as SDF1/CXCR4,
VLA4/VCAM-1, or CD44/osteopontin, play an important role in homing of HSC in the hematopoietic niche.
There is some evidence that disruption of the ligand-receptor complex leads to the egress of HSCs to the
peripheral blood. The aim of the present study was the evaluation of constitutive polymorphism of genes
encoding cytokines and receptors present in the HSC niche and their impact on the efﬁcacy of mobilization of
HSCs in patients with hematological malignancies. We enrolled 110 patients (60 females and 50 males) in the
study. The median age of the patients was 55 (range, 22 to 69) years. The group consisted of patients with
multiple myeloma (n ¼ 74), non-Hodgkin lymphoma (n ¼ 19), Hodgkin lymphoma (n ¼ 15), or acute myeloid
leukemia (n ¼ 2). The mobilization procedures comprised chemotherapy and subsequent granulocyte-colony
stimulating factor (G-CSF) at a dose of 10 mg/kg daily. The poor mobilizers group was deﬁned according to
Italian National Bone Marrow Transplant Registry criteria: patients with peak CD34þ in the peripheral
blood < 20/mL or total yield < 2  106 CD34þ cells/kg body weight in maximum 3 aphereses. Genotyping was
performed using standard PCR-based assays. The group of patients (N ¼ 108) who achieved minimal
threshold for collections (CD34þ at least 10/mL) proceeded to apheresis. The median total yield of CD34þ in
this group was 5.6  106 cells/kg body weight, whereas the median number of cells collected during the ﬁrst
apheresis was 3.3  106 cells/kg body weight. Median number of days of G-CSF treatment before ﬁrst
apheresis was 10. Fifteen patients fulﬁlled the criteria for poor mobilizer. The group of poor mobilizers had
higher frequency of TT genotype in rs13347 (CD44) gene (CCþ CT versus TT P ¼ .047). Patients homozygous
for T allele had a lower total yield of CD34þ cells/kg body weight than the group with allele C (median,
3.7  106/kg versus 5.8  106/kg; P ¼ .019) and a lower number of CD34þ cells gathered during ﬁrst apheresis
(.95  106/kg versus 3.3  106/kg, P ¼ .04). Multivariate logistic regression analysis revealed that the CD44 TT
genotype was the only factor associated with 5-fold higher risk of poor mobilization (P ¼ .037). Polymorphic
variants of CXCR4 and VCAM-1 did not signiﬁcantly inﬂuence the efﬁcacy of HSCs mobilization in our group
of patients. In conclusion, our results indicate that among investigated single nucleotide polymorphisms
(SNPs), only CD44 rs13347 has an impact on the efﬁcacy of HSCs mobilization in patients with hematologic
malignancies. CD44 SNPs analysis may be helpful for predicting the poor mobilizers population who may
beneﬁt from newer modalities using adhesion molecules inhibitors.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
The hematopoietic stem cells (HSC) niche contains different
types of cells, including macrophages, osteoblasts, mesen-
chymal stem cells, and endothelial progenitors. All of these
interact and form a unique microenvironment, necessary for
the appropriate function and preservation of HSCs in the
quiescent state, and take a major part in the process of mobi-
lization and homing [1-7]. The so-called osteoblastic part of theedgments on page 990.
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14.03.019HSC niche is responsible for maintenance of dormant, resting
HSCs, whereas active, dividing HSCs are located mainly near
endothelial cells in the vascular part of the niche.
Most transplantation centers use HSCs collected from the
peripheral blood as the main source of cells for trans-
plantation [8-11]. The CD34þ cells are mobilized from the
bone marrow by granulocyte-colony stimulating factor
(G-SCF) alone or in combination with chemotherapy [11]. The
exact mechanisms of mobilization are still not clear [12-14].
The currently accepted theory explains themechanism of HSC
mobilization by a G-CSFemediated release of proteolytic en-
zymes from neutrophils, including metalloproteinases, lead-
ing to profound changes in the HSC microenviroment [15-18].
The SDF1/CXCR4 axis plays a key role in mobilization ofTransplantation.
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as from the HSCs [16,17]. A single nucleotide polymorphism
(SNP) of CXCL12-CXCL12-801A is associated with a higher
number of G-CSFemobilized CD34þ cells in patients [19]. The
data concerning CXCL12-801A polymorphism in the context
of on HSC mobilization in healthy donors are conﬂicting
[20,21]. The inﬂuence of other polymorphisms on the mobi-
lization outcome in patients with hematological malignancies
has not been studied so far.
During G-CSFestimulated mobilization of HSCs in hu-
mans, a decrease in CD44 expression has been noted [22].
CD44 is a surface glycoprotein receptor, which binds
different ligands, including hyaluronic acid and osteopontin
(OPN) [23,24]. Adhesion molecules, responsible for cell-to-
cell and cell-to-stromal matrix interactions, modulate HSC
development in the niche. Vascular cell adhesion molecule
1 (VCAM-1) is expressed by osteoblasts and stromal cells and
interacts with very late antigen 4 (VLA-4) present on the
HSCs. Disruption of VLA4/VCAM1 results in mobilization of
HSC in humans [25,26].
The aim of the present study was to thoroughly evaluate
constitutive polymorphisms of several genes encoding cy-
tokines and receptors present in the HSC niche, including
CD44, VCAM-1, and CXCR4, and to assess their impact on the
efﬁcacy of mobilization of CD34þ hematopoietic progenitor
cells in patients scheduled for autologous transplantation. To
our knowledge, the impact of the polymorphisms of CD44,
CXCR4, and VCAM1 on the effects of mobilization in patients
with hematological malignancies has not been evaluated
so far.
PATIENTS AND METHODS
One hundred and ten patients 110 (60 females and 50 males) were
enrolled in the study. (Table 1) The median age was 55 years (range, 22 to
69). All of the patients were eligible for autologous HSC mobilization andTable 1
Characteristics of the Patients
Characteristics Value
Age, median (range), yr 55 (22-69)
Sex (female/male) 60/50
Multiple myeloma 74 (32 CR, 25 VGPR, 17 PR)
Mobilization procedure
Cyclophosphamide 58
DCEP 16
Lymphoma 34
Hodgkin lymphoma 15 (5 CR, 10 PR)
Non-Hodgkin lymphoma 19 (9 CR, 10 PR)
Diffuse large B cell lymphoma 13 (6 CR, 7 PR)
Mantle cell lymphoma 4 (3 CR, 1 PR)
AILD lymphoma 1 PR
ALCL 1 PR
Mobilization procedure in lymphoma
DHAP 16
ICE 14
IGEV 1
Etoposide 1
Cyclophosphamide 1
AraC 1
Acute myeloid leukemia 2 (2 CR)
Mobilization procedure:
HDaraC 2
CR indicates complete remission; VGPR, very good partial remission (only
multiple myeloma); PR, partial remission; DCEP, dexamethasone, cyclo-
phosphamide, etoposide, and cisplatinum; AILD, Angioimmunoblastic
lymphadenopathy; ALCL, Anaplastic large cell lymphoma; DHAP, dexa-
methasone, cytarabine, cisplatin; ICE, ifosfamide, carboplatin, etoposide;
IGEV, ifosfamide, gemcitabine, vinorelbine, prednisone; AraC, cytosine
arabinoside; HDaraC, high dose cytosine arabinoside.
Remission status is prior to mobilization procedure. Chemotherapy regi-
mens at standard doses.transplantation. The group consisted of patients with multiple myeloma
(n ¼ 74), non-Hodgkin lymphoma (n ¼ 19), Hodgkin lymphoma (n ¼ 15),
and acutemyeloid leukemia (n¼ 2). Themobilization procedures comprised
chemotherapy and subsequent G-CSF administration at a dose of 10 mg/kg
daily. The poor mobilizer group was deﬁned according to Italian National
Bone Marrow Transplant Registry criteria: patients with peak CD34þ in the
peripheral blood < 20/mL or total yield < 2  106 CD34þ/kg in 3 aphereses
[27]. The study was performed in accordance with the ethical standards of
the Ethics Committee of the Medical University of Lodz and with the Hel-
sinki Declaration of 1975, revised in 1983.
Patients who achievedminimal threshold for collections (CD34þ at least
10/mL) proceeded to apheresis. This group comprised 108 patients. They
were included in further analyses, regarding the collection efﬁcacy. (Table 2)
Polymorphisms of CD44 rs13347, VCAM1 rs1041163, and CXCR4
rs2680880 were evaluated. Genotyping was performed using standard PCR-
based assays. The SNPs studied in our group had been chosen based on the
literature review and their potential functionality. We searched for SNPs
with less frequent homozygous allele present in more than 10% of Caucasian
population. Additionally, we looked for SNPs located in either 50UTR or
30UTR region. We decided to choose the SNP associated with efﬁcacy of HSC
mobilization in healthy people described byMartin-Antonio [28]: located in
50UTR region (CXCR4 rs2680880 and VCAM1 rs1041163) and located in 30UTR
(CD44 rs13347).
Genotyping
Genomic DNA was isolated from the cryopreserved apheresis material
(N¼ 108) or the peripheral blood in patients from the poormobilizers group,
who did not reach the CD34þ threshold required for collection. PCR was
performed using a thermocycler Biometra T Personal (Biometra, Gottingen,
Germany). DNA was extracted according to the GTC method. The 3 poly-
morphisms (SNP) rs 1041163 T>C in the VCAM 1 gene, rs 2680880 CXCR4
gene, and rs13347 CD44 gene were analyzed using .1 mg genomic DNA,
TaqMan Genotyping Master Mix 2x and .5 mM speciﬁc primers (Life Tech-
nologies, Carlsbad, CA). The reactions were performed at 95C for 5 minutes
due to AmpliTaqGold polymerase activation (Roche Molecular Systems,
Branchburg, NJ) then 40 cycles at 15 seconds at 92C and 60 seconds at 60C.
The genotypes were determined through comparison ﬂuorescence.
Detection of Gene Expression Using Real-Time PCR Method
Total RNA was extracted from the samples using a RNA extraction
reagent, TRIzol (Invitrogen, Life Technologies). Five micrograms of isolated
RNA were reverse transcribed at 42C for 60 minutes in a total 20 mL
reaction volume using the ImProm-II Reverse Transcription System kit
(Promega, Madison, WI). Obtained cDNAwas used in real-time PCR reaction.
Real-time PCR based on TaqMan technology was performed using
MasterMix (Applied Biosystems, Life Technologies) prepared according to
the FastStart Universal Probe Master (ROX) (Roche Applied Science, Man-
nheim, Germany). Probes and primers were designed using the online
Universal Probe Library (www.universalprobelibrary.com). Primer se-
quences and probe numbers are as follows: VCAM-1 (forward, 50-
CCGGATTGCTGCTCAGATTGGA-30 , reverse, 50-AGCGTGGAATTGGTCCCCTCA-
30 , probe: #6), CD44 (forward, 5-TCCAGGCAACTCCTAGTAGTA-30 , reverse,
50-CTGTCCCTGTTGTCGAAT-30 , probe: #49), and 18sRNA (forward 50 CCGA-
TAACGAACGAGACTCTGG-30 , reverse 50 TAGGGTAGGCACACGCTGAGCC-30
probe: #29), which was used as internal control for real-time PCR.Table 2
Mobilization and Collection Efﬁcacy
Mobilization and Collection Efﬁcacy n
All patients evaluated 110
Patients who reached minimal number of CD34þ for apheresis 108
Patients who gathered at least minimal amount of cells for HSCT
(minimum 2  106 CD34þ/kg)
103
Poor mobilizer according to GITMO criteria 15
No. of aphereses required to gather 2  106 CD34þ cells
1 apheresis 72
2 aphereses 22
3 aphereses 8
4 aphereses 1
Patients who gathered optimal number of cells (at least 4  106
CD34þ/kg)
85
Number of aphereses required to gather 4  106 CD34þ cells
1 apheresis 46
2 aphereses 33
3 aphereses 5
HSCT indicates hematopoietic stem cell transplantation; GITMO, Italian
National Bone Marrow Transplant Registry.
Figure 1. Total CD34þ cells yield in patients according to CD44 alleles: carriers
of C allele and patients with TT allele.
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cDNA, 25 mL FastStart Universal Probe Master (ROX) 2x, 250 nM probe, and
1 mM of each primer. Ampliﬁcationwas performed for 10 minutes at 95C to
activate FastStart Taq DNA polimerase and 40 rounds of 15 seconds at 95C
and 1 minute at 60C for ampliﬁcation and signal analysis. 7900HT Fast Real
Time OCR System (Applied Biosystems, Life Technologies) was used to detect
ampliﬁcations. Each sample was assayed in triplicate in independent re-
actions. Real-time PCR data were automatically calculated with the data
analysis module. The results were analyzed according to the 2DDCt method.
Validation of PCR efﬁciency was performed with a standard curve. Standard
curves were prepared for each gene by serial dilution.
Messenger RNA expression for CD44 and VCAM-1 was evaluated by
real-time reverse transcription-PCR assay using ABI Prism 7000
Sequence Detection System (Applied Biosystems, Life Technologies).
Total RNA was extracted from cryopreserved apheresis samples using
TRIzol (Invitrogen, Life Technologies).
Statistical Analysis
The results are presented as medians and ranges for continuous vari-
ables. SNPs were analyzed for deviation from the Hardy-Weinberg equilib-
rium, using the chi-square test. Three subgroups were established for the
genotype in each polymorphism (homozygous more frequent, heterozygous
and homozygous less frequent). The Wilcoxon matched-pair test was used
to compare groups of dependent continuous variables. The chi-square test
with Yates correction and the exact Fischer test were used to investigate the
dependence between 2 categorical variables. Correlations between variables
were assessed by the Spearman rank correlation coefﬁcient (r). Multivariate
logistic regression was performed. Comparisons and correlations were
considered signiﬁcant if P < .05.
RESULTS
Mobilization Efﬁcacy
The group of patients (N ¼ 108) who achieved minimal
threshold for collections (CD34þ at least 10/mL) proceeded to
apheresis. The median total yield of CD34þ in this group was
5.6  106/kg, whereas the median number of cells collected
during ﬁrst apheresis was 3.3  106/kg. The median number
of days of G-CSF treatment before ﬁrst apheresis was 10.
Patients with multiple myeloma had higher number of
CD34þ/mL (median, 75; range, 6 to 530) than patients with
other disorders (median, 43; range, 2 to 231; P ¼ .002) and a
higher CD34þ total yield (6.3  106/kg for multiple myeloma
and 4.4 for non-multiple myeloma patients, P ¼ .01). Mobi-
lization efﬁcacy was comparable in males and females.
Fifteen patients fulﬁlled the criteria for poor mobilizers.
Allele Frequencies in CD44, VCAM1, and CXCR4
All the observed polymorphisms were in the Hardy-
Weinberg equilibrium. In the CD44 gene, we observed the
homozygous CC genotype in 58 out of 110 patients (53%),
heterozygous CT in 41 (37%), and homozygous TT in 11 (10%)
patients. Results concerning the VCAM1 polymorphismwere
as follows: TT 56 of 110 (51%), CT 44 of 110 (40%), and CC in 10
of 110 (9%) patients. In the CXCR4 gene evaluation, we noted
AA genotype in 41 of 110 (37%) patients, heterozygous AT in
49 of 110 (45%), and TT in 20 of 110 (18%) patients.
CD44 Polymorphism
The median CD44 mRNA expression in the study group
was .24 (range, .08 to .68). TT homozygous genotype resulted
in an increased mRNA expression: median of .52 (range, .16
to .58), compared with the carriers of allele C (median, .27;
range, .17 to .4 in CC and median, .15; range, .08 to .68 in CT
genotype; P < .001). CD44 mRNA expression strongly
correlated with poor mobilization (r ¼ -.2; P ¼ .018).
The group of poor mobilizers had a higher frequency of
TT genotype in the rs13347 (CD44) gene (CCþCT versus TT,
P ¼ .047). The difference was even more pronounced in
patients with multiple myeloma (n ¼ 72; P ¼ .027). Four of
15 patients in the poor mobilizers group were homozygousfor T allele (26%), whereas among “good mobilizers” it was
only 7 of 95 (7%) (P ¼ .02). Patients with TT genotype had a
lower number of CD34þ cells collected during the ﬁrst
apheresis (.95  106/kg versus 3.3  106/kg, P ¼ .04) and a
lower total yield of CD34þ/kg than the group with allele
C (median, 3.7  106/kg versus 5.8  106/kg; P ¼ .019)
(Figure 1). The presence of TT genotype correlated with a
lower CD34þ total yield (r ¼ .3, P ¼ .01), lower number of
CD34þ collected at the ﬁrst apheresis (r ¼ .2, P ¼ .40) and
being a poor mobilizer (r ¼ .23, P ¼ .02). The results are
shown in Table 3 and clinical characteristics of patients
with TT genotype and allele C carriers are given in Table 4.
Results of univariate analysis of the factors predicting
poor mobilization are presented in Table 5. Multivariate
logistic regression analysis including age, gender, diagnosis
(multiple myeloma versus others), number of previous
treatment lines and CD44 polymorphism (TT versus CTþCC)
revealed TT genotype was the only factor associated with a
5-fold higher risk of poor mobilization (P ¼ .037).
VCAM 1 Polymorphism
Patients with CC genotype had a higher VCAM1 mRNA
expression (median, .63; range, .6 to .7) than the T carriers
(median, .5; range, .44 to .78; P ¼ .002).
There was no difference in the frequency of CC genotype
in poor mobilizers or good mobilizers (2 of 15 [13%] versus
8 of 95 [8.4%], respectively; P ¼ .50). The details of the
mobilization efﬁcacy in VCAM1 polymorphic variants are
given in Table 6.
CXCR4 Polymorphism
There were 3 of 15 (20%) patients with TT genotype in the
poor mobilizers group and 17 of 95 (18%, P ¼ .80) with TT
genotype in the goodmobilizers group. Polymorphic variants
of CXCR4 did not inﬂuence signiﬁcantly the efﬁcacy of HSC
mobilization in our group of patients. The efﬁcacy of mobi-
lization procedures in different polymorphic variants in
CXCR4 are presented in Table 7.
DISCUSSION
The efﬁcacy of mobilization of HSC in healthy donors and
in patients with cancer is a problem addressed in numerous
publications [29-33]. Clinical factors that predict the efﬁcacy
of CD34þ cell mobilization in patients with hematologic
malignancies include gender, age, number of previous
intensive regimens, radiotherapy, and type of disease, among
others [29-33]. The results of this study indicate that the type
Table 5
Univariate Analysis of Factors Associated with Probability of Poor
Mobilization
Factor Odds Ratio
(95% CI)
P
Value
Age 1.1 (.3-3.4) .80
Disease MM versus other .36 (.1-1.1) .07
Number of treatment lines before mobilization
(more than 2 versus 1 or 2)
1.6 (.46-5.9) .40
Male versus female 1.9 (.64-6.0) .20
CD44 polymorphism (TT versus CCþCT) 4.6 (1.1-18) .03
MM indicates multiple myeloma; CI, conﬁdence interval.
Table 3
Inﬂuence of CD 44 Polymorphism on Mobilization Efﬁcacy
Outcome CC (n ¼ 58) CT (n ¼ 39) TT (n ¼ 1) P
Value
CD34þ/mL 73 (8-556) 54 (6-446) 19 (6-230) .28
Cells collected during
ﬁrst apheresis
( 106 CD34þ/kg)
3.76 (.3-32) 3.3 (.4-24.7) 1.0 (.3-1.9) .40
Total CD34þ yield
( 106 CD34þ/kg)
5.7 (1.7-31.9) 6.0 (1.3-42.9) 3.7 (.8-18.2) .07
CCþCT
(n ¼ 97)
TT
(n ¼ 11)
P
Value
CD34þ/mL 56 (8-556) 21 (18-225) .10
Cells collected during ﬁrst
apheresis 
106 CD34þ/kg
3.2 (.42-32) 1.2 (.3-11) .04
Total CD34þ yield ( 106 CD34þ/kg) 5.8 (1.5-42) 3.6 (.9-18) .01
Data presented are median (range).
Bold values are statistically signiﬁcant (P < .05)
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with previous observations. Although several trials evaluated
the topic, there is still a lack of good predictive factors for
successful mobilization. Hence, the hunt is on for new pa-
rameters to serve as factors that can predict the mobilizing
efﬁcacy of CD 34þ.
To our knowledge, the inﬂuence of polymorphisms in
CD44, VCAM1, and CXCR4 genes have not been studied in
the context of mobilization efﬁcacy in patients scheduled
for autologous transplantation. In our group of patients,
we observed a higher frequency of TT genotype in rs13347
(CD44) gene in the poor mobilizers group. The difference
was even more pronounced in patients with multiple
myeloma. TT homozygous genotype resulted in a higher
CD44 mRNA expression at the time of apheresis in com-
parison with carriers of C allele. Patients homozygous for
T allele had a lower total yield of CD34þ/kg than the group
with allele C and a lower number of CD34þ cells gathered
during the ﬁrst apheresis. Martin-Antonio et al. evaluated
the inﬂuence of several single gene polymorphisms on the
efﬁcacy of HSC mobilization in healthy donors [28]. In their
study, carriers of allele C in the CD44 gene (CD44-2392 C)
reached a higher number of CD 34þ cells in peripheral
blood and gathered a higher number of HSC per kilogramTable 4
Characteristics of Patients with TT Allele and C Carriers in CD44
Characteristic CCþCT Allele TT Allele
No. of patients 99 11
Sex (female/male) 57/42 3/8
Age, median (range), yr 54.8 (22-69) 54.3 (27-62)
Diagnosis
MM 68 6
HL 12 3
NHL 17 2
AML 2 0
No. of treatment lines
before mobilization, median (range)
1 (1-5) 2 (1-3)
Response to treatment
CR 43 5
Not in CR 36 6
PR 12 5
VGPR 24 1
MM indicates multiple myeloma; HL, Hodgkin lymphoma; NHL, non-
Hodgkin lymphoma; AML, acute myelogenous leukemia; CR, complete
remission; PR, partial remission; VGPR, very good partial remission (only
multiple myeloma).
Remission prior to mobilization procedure.of body weight [28]. The authors observed a decrease in
CD44 expression at the time of apheresis as compared
with the baseline values before G-CSF treatment. This
tendency was not present in recessive TT genotype, charac-
terized also by the lowest mobilization yield [28]. In our
group of patients, we observed higher CD44 mRNA expres-
sion in TT genotype, which may result from different mRNA
kinetics during mobilization in polymorphic CD44 variants,
as reported by Martin-Antonio [28]. Our results regarding
the inﬂuence of CD44 polymorphism on the efﬁcacy of HSC
mobilization in patients with hematological malignancies
are in line with the observations of Martin-Antonio et al.
concerning healthy donors [28].
Higher CD44 mRNA expression in TT genotype, observed
in our study, may explain lowermobilization potential in that
group of patients. The SNP location in 30UTR of CD44 can
potentially result in a change in the binding ability of
different microRNAs among the 2 different alleles. Micro-
RNAs are short, noncoding RNA molecules, which, by tar-
geting mRNAs, cause mRNA degradation or translational
repression, thus playing a key role in regulating gene
expression. Jiang et al. [34] evaluated CD44 rs13347 poly-
morphisms in patients with breast cancer. The authors
observed that miR-509-3p binds and negatively regulates
the transcription of CD44 in the presence of rs13347 C allele.
As a result, higher CD44 protein was detected in T carriers as
compared with carriers of CC genotype [34].
A complex network of different molecules interplay to
maintain HSCs in a quiescent state and take part in mobili-
zation [35]. CD44 is the multifunctional glycoprotein recep-
tor that can bind different ligands, including hyaluronic acid
and OPN. HSCs can be triggered to migrate to peripheral
blood in the process of mobilization by different stimuli.
G-CSF exerts its activity by binding with its receptor onTable 6
Inﬂuence of VCAM-1 Polymorphism on Mobilization Efﬁcacy
Outcome TT (n ¼ 56) CT (n¼ 42) CC (n ¼ 10) P
Value
CD34þ/mL 70 (8-556) 51 (8-385) 61 (10-230) .27
Cells collected
during ﬁrst apheresis
( 106 CD34þ/kg)
3.2 (.3-32) 2.9 (.4-25) 3.0 (.8-10.9) .80
Total CD34þ yield
( 106 CD34þ/kg)
5.7 (1.4-43) 6.2 (.9-25) 4.3 (1.4-25) .40
TT þ CT
(n ¼ 98)
CC
(n ¼ 10)
P
Value
CD34þ/mL 53.4 (8-556) 61 (10-231) .60
Cells collected during ﬁrst apheresis
106 CD34þ/kg
3.2 (.3-32) 2.9 (.6-11) .50
Total CD34þ yield ( 106 CD34þ/kg) 5.6 (.8-42) 4.4 (1.6-25) .27
Data presented are median (range).
Table 7
Inﬂuence of CXCR4 Polymorphism on Mobilization Efﬁcacy
Outcome AA
(n ¼ 41)
AT
(n ¼ 48)
TT
(n ¼ 19)
P
Value
CD34þ/mL 45 (8-449) 73 (8-555) 50 (10-3830) .30
Cells collected during
ﬁrst apheresis
( 106 CD34þ/kg)
2.7 (.4-25) 3.5 (.4-32) 3.8 (.3-14.9) .50
Total CD34þ yield
( 106 CD34þ/kg)
5.3 (.8-24) 6.1 (1.6-42) 5.8 (1.4-24) .80
AAþAT
(n ¼ 89)
TT
(n ¼ 19)
P
Value
CD34þ/mL 54 (10-556) 50 (8-381) .80
Cells collected during ﬁrst apheresis 
106 CD34þ/kg
3.2 (.4-32) 3.7 (.3-15) .90
Total CD34þ yield ( 106 CD34þ/kg) 5.6 (1.2-43) 6.6 (1.9-25) .90
Data presented are median (range).
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since the presence of a G-CSF receptor is not solely required
for mobilization [15]. During G-CSFemediated mobilization,
neutrophil degranulation occurs, leading to upregulation of
the matrix metalloproteases, which in turn cause cleavage of
CD44 [22,24].
Hyaluronic acid, a glycosaminoglycan, is a key structural
and functional component present abundantly in the
hematopoietic niche, and its interaction with CD44 is
responsible for HSC trafﬁcking to bone marrow during
transplantation [24,36]. The diversity of the CD44 structure
resulting from its post-translational modiﬁcations and
polymorphic variants can inﬂuence the afﬁnity of the re-
ceptor for hyaluronic acid [22,24]. OPN, another CD44
counterpart, is a glycosylated phosphoprotein, produced
mainly by osteoblasts. OPN is a survival factor for many tis-
sues, exerts antiapoptotic activity, and is a biomarker of
numerous neoplastic disorders [37-41]. On the other hand,
OPN inhibits HSC proliferation and is involved in the control
of the HSC cycle; thus, it takes part in HSC migration and
appropriate localization in the bone marrow niche after
transplantation [42]. Moreover, it also controls angiogenesis,
enhances migration, and decreases apoptosis of endothelial
cells. Angiogenesis is crucial for tissue repair from damage
caused by chemotherapy, including the most sensitive he-
matopoietic cells [4-6] and takes an important part in HSCs
mobilization and homing [4-6,43,44]. In our previous study,
the number of endothelial precursors evaluated early after
chemotherapy cessation and after the beginning of G-CSF
treatment inﬂuenced the timing of CD34þ collection [43].
Moreover, a lower number of apoptotic endothelial pre-
cursors after the start of G-CSF administrationwas associated
with a lower number of aphereses needed to get the minimal
number of cells for transplantation. Both observations indi-
cate the supportive function of bone marrow microvascula-
ture in the mobilization of CD34þ cells to the peripheral
blood [43]. The impact on angiogenesis may explain the in-
ﬂuence of CD44 polymorphism on the efﬁcacy of mobiliza-
tion by affecting the CD44/OPN axis. One of the CD44 forms
exerts a unique function, being a hematopoietic cell E/L
selectin ligand (HCELL). HCELL is a glycovariant of CD44 and
acts as the most potent E- and L-selectin ligand on human
hematopoietic cells [45], with increased expression after
G-CSF administration [46]. CD44/OPN, as well CD44/hyal-
uronic acid and HCELL/selectins interactions, all take part in
HSCs mobilization, and polymorphic variants of the CD44
gene inﬂuence different complex pathways of the hemato-
poietic niche regulatory mechanisms.We have seen no inﬂuence of the VCAM-1 gene poly-
morphism on the efﬁcacy of HSCs mobilization. In contrast,
Martin-Antonio observed that genetic variants in VCAM-1
(VCAM-1 1591C) showed a lower number of collected
CD34þ/kg of body weight and a lower number of CD34þ cells
in the peripheral blood at the time of apheresis [28]. In
healthy individuals (donors for allogeneic transplantation),
G-CSF is applied for mobilization of HSCs from bone marrow,
whereas in patients with neoplastic disorders, G-CSF is used
in combination with chemotherapy to cause egress of HSCs
from the bone marrow to the peripheral blood. G-CSFesti-
mulated mobilization of HSC in mice is accompanied with
reduced expression of VCAM1 in bone marrow HSCs and
endothelial cells [47]. Mechanisms of mobilization caused by
chemotherapy in combination with G-SCF have been rarely
studied.
In our group of patients, polymorphism of CXCR4 did not
inﬂuence the efﬁcacy of HSCmobilization. A disruption of the
SDF1/CXCR4 axis is a main step in the egress of HSCs to the
peripheral blood. A key mechanism of the G-CSFeinduced
mobilization is downregulation of the CXCR4 expression in
the bone marrow [18]. Martin-Antonio reported a signiﬁ-
cantly lower total CD34þ yield in the AA genotype. Similar to
our study, Martin-Antonio et al. did not observe the inﬂuence
of the CXCR4 polymorphism on the number of CD34þ cells
in peripheral blood at the time of apheresis [28]. Some
discrepancies in donors’ characteristics and mobilization
schedules may be responsible for different results concern-
ing the VCAM1 and CXCR4 polymorphisms between our
study and Martin-Antonio’s.
In conclusion, our results indicate that among investi-
gated SNPs, only CD44 rs13347 has an impact on the efﬁcacy
of HSCs mobilization in patients with hematologic malig-
nancies. Furthermore, CD44 SNPs analysis may be helpful for
predicting the poor mobilizers population that may beneﬁt
from newer modalities using adhesion molecules inhibitors.
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